Sonnet (SONN) falls 7.67% on Moderate Volume September 14

Equities Staff  |

Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN), a Princeton, New Jersey, company, fell to close at $0.56 Tuesday after losing $0.0469 (7.67%) on volume of 7,028,064 shares. The stock ranged from a high of $0.61 to a low of $0.55 while Sonnet’s market cap now stands at $14,098,145.

About Sonnet BioTherapeutics Holdings Inc

Founded in 2011, Sonnet Biotherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and 'hitch-hikes' on human serum albumin (HSA) for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Visit Sonnet BioTherapeutics Holdings Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Sonnet BioTherapeutics Holdings Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Sonnet BioTherapeutics Holdings Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Cross Border Money Transfer Company Remitly Seeks $7 Billion IPO Valuation
Intuit To Acquire Mailchimp for $12 Billion in Cash and Stock
Consumer Brands Association Presses White House for More Clarity on Vaccine Mandates
Freshworks Shooting for $9 Billion IPO Valuation at Top End of Filing Range
Fauci Supports COVID-19 Vaccine Mandate for All Domestic Air Travel
Jobless Claims Fall to 310,000 — Lowest in Nearly 18 Months
200 Westerners Board Qatar Airways Flight From Kabul
Pennsylvania Republican Lawmakers Launch 'Election Integrity' Investigation



Market Movers

Sponsored Financial Content